{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Priming&page=16",
    "query": {
      "intervention": "Priming",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 593,
    "total_pages": 60,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Priming&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Priming&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T16:00:42.975Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00888940",
      "title": "Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bloodloss",
        "Surgical Procedures, Operative"
      ],
      "interventions": [
        {
          "name": "Ecallantide",
          "type": "DRUG"
        },
        {
          "name": "Cyklokapron(R)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 243,
      "start_date": "2009-06",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2015-08-10",
      "last_synced_at": "2026-10-18T16:00:42.975Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00888940"
    },
    {
      "nct_id": "NCT00870987",
      "title": "Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "DNA vaccine prime",
          "type": "BIOLOGICAL"
        },
        {
          "name": "adenovirus type 5 vaccine boost",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 82,
      "start_date": "2009-05",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-10-18T16:00:42.975Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00870987"
    },
    {
      "nct_id": "NCT00801697",
      "title": "Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DNA Vaccine placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd35",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd35 placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd5",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd5 placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 192,
      "start_date": "2009-02",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-10-18T16:00:42.975Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00801697"
    },
    {
      "nct_id": "NCT00834665",
      "title": "Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "hTERT vaccine, GM-CSF, PCV, T cell infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GM-CSF, PCV, T cell infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 59,
      "start_date": "2006-12",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2019-10-23",
      "last_synced_at": "2026-10-18T16:00:42.975Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00834665"
    },
    {
      "nct_id": "NCT00076752",
      "title": "Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Erythematosus, Systemic"
      ],
      "interventions": [
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Rituxan (rituximab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "15 Years to 40 Years"
      },
      "enrollment_count": 9,
      "start_date": "2004-01-30",
      "completion_date": "2013-10-15",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-10-18T16:00:42.975Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076752"
    },
    {
      "nct_id": "NCT03292471",
      "title": "Effects of rTMS on Brain Activation in Aphasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Aphasia, Acquired"
      ],
      "interventions": [
        {
          "name": "Transcranial Magnetic Stimulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2018-01-01",
      "completion_date": "2019-12-31",
      "has_results": true,
      "last_update_posted_date": "2022-12-20",
      "last_synced_at": "2026-10-18T16:00:42.975Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03292471"
    },
    {
      "nct_id": "NCT06919016",
      "title": "A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1-RNA in Adults Without HIV",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "DV700P-RNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DV701B1.1-RNA",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 45,
      "start_date": "2025-08-06",
      "completion_date": "2027-03-25",
      "has_results": false,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-10-18T16:00:42.975Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06919016"
    },
    {
      "nct_id": "NCT04944134",
      "title": "COVID-19 Antibody Levels After Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Vaccine Preventable Disease"
      ],
      "interventions": [
        {
          "name": "COVID-19 Vaccination",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2021-06-09",
      "completion_date": "2022-04-01",
      "has_results": false,
      "last_update_posted_date": "2022-08-01",
      "last_synced_at": "2026-10-18T16:00:42.975Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04944134"
    },
    {
      "nct_id": "NCT03901547",
      "title": "Emotion Regulation and Burnout Impact on Communication Documentation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Communication"
      ],
      "interventions": [
        {
          "name": "Communication Skills Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Profile feedback",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Maslach burnout inventory",
          "type": "OTHER"
        },
        {
          "name": "Emotion Regulation Skills Question (ERSQ)",
          "type": "OTHER"
        },
        {
          "name": "Semi-structured interview",
          "type": "OTHER"
        },
        {
          "name": "Priming",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-09-15",
      "completion_date": "2022-01-01",
      "has_results": false,
      "last_update_posted_date": "2023-08-01",
      "last_synced_at": "2026-10-18T16:00:42.975Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03901547"
    },
    {
      "nct_id": "NCT02986854",
      "title": "Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infections, Meningococcal"
      ],
      "interventions": [
        {
          "name": "Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "15 Years to 55 Years"
      },
      "enrollment_count": 704,
      "start_date": "2016-12-08",
      "completion_date": "2017-12-07",
      "has_results": true,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-10-18T16:00:42.975Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02986854"
    }
  ]
}